{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:56:37Z","timestamp":1791284197418,"version":"4.1.0"},"reference-count":75,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031723","name":"Amgen GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031723","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2452054","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T04:21:37Z","timestamp":1736828497000},"page":"207-220","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Goethe University Hospital Frankfurt","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schulte","sequence":"additional","affiliation":[{"name":"Amgen GmbH","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9521-3898","authenticated-orcid":false,"given":"Nils","family":"Kossack","sequence":"additional","affiliation":[{"name":"WIG2 GmbH Scientific Institute for Health Economics and Health System Research","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1883-4113","authenticated-orcid":false,"given":"Marc","family":"Pignot","sequence":"additional","affiliation":[{"name":"Berlin Center for Epidemiology and Health Research, ZEG Berlin GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schultze","sequence":"additional","affiliation":[{"name":"Berlin Center for Epidemiology and Health Research, ZEG Berlin GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Feldhus","sequence":"additional","affiliation":[{"name":"Amgen GmbH","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1637-8"},{"key":"e_1_3_3_3_1","unstructured":"World Health Organization (WHO). Global report on psoriasis; 2016 [cited 2023 Jan 31]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241565189"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S179182"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000511868"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184347"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35"},{"key":"e_1_3_3_10_1","unstructured":"Global Psoriasis Atlas. Statistics; 2022 [cited 2023 Jan 31]. Available from: https:\/\/www.globalpsoriasisatlas.org\/en\/statistics"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_3_3_12_1","unstructured":"Augustin M Glaekse G Hagenstr\u00f6m K. Psoriasisreport: Pr\u00e4vention Versorgung und Innovation; 2023 [cited 2023 Jan 31]. Available from: https:\/\/www.tk.de\/resource\/blob\/2105142\/9fc664ddbfa42f94c3796a2211469f7f\/hautreport-psoriasis-lang-data.pdf"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01522-8"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.23736\/s0392-0488.16.05516-4"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/ptt.S54070"},{"issue":"4","key":"e_1_3_3_16_1","first-page":"13","article-title":"Recommendations for initiating systemic therapy in patients with psoriasis","volume":"12","author":"Martin G","year":"2019","unstructured":"Martin G, Young M, Aldredge L. Recommendations for initiating systemic therapy in patients with psoriasis. J Clin Aesthet Dermatol. 2019;12(4):13\u201326.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_17_1","unstructured":"National Institute for Health and Care Excellence. Psoriasis: assessment and management; 2017 [cited 2023 Jan 31]. Available from: www.nice.org.uk\/guidance\/cg153"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_3_3_19_1","volume-title":"Cyclosporine for moderate to severe plaque psoriasis in adults: a review of clinical effectiveness and safety","author":"Singh K","year":"2018","unstructured":"Singh K, Arg\u00e1ez C. CADTH rapid response reports. In: Cyclosporine for moderate to severe plaque psoriasis in adults: a review of clinical effectiveness and safety. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2011"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1472097"},{"issue":"8","key":"e_1_3_3_22_1","first-page":"861","article-title":"Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center","volume":"12","author":"Au SC","year":"2013","unstructured":"Au SC, Madani A, Alhaddad M, et\u00a0al. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. J Drugs Dermatol. 2013;12(8):861\u2013866.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0364"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946"},{"issue":"2","key":"e_1_3_3_25_1","first-page":"221","article-title":"Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL","volume":"17","author":"Stein Gold L","year":"2018","unstructured":"Stein Gold L, Bagel J, Lebwohl M, et\u00a0al. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17(2):221\u2013228.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13150"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14832"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_3_3_30_1","unstructured":"European Medicines Agency. Otezla: summary of product characteristics; 2015 [cited 2023 Mar 7]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/otezla"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0045"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0097"},{"key":"e_1_3_3_33_1","unstructured":"Wissenschaftliches Institut f\u00fcr Gesundheits\u00f6konomie und Gesundheitssystemforschung. WIG2; 2023 [cited 2023 Nov 21]. Available from: https:\/\/www.wig2.de\/english-summary.html"},{"key":"#cr-split#-e_1_3_3_34_1.1","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). ICD-10-GM Version 2022. Systematisches Verzeichnis: internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme 10. Revision German Modification"},{"key":"#cr-split#-e_1_3_3_34_1.2","unstructured":"2022 [cited 2023 Jan 31]. Available from: https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Services\/Downloads\/_node.html"},{"key":"e_1_3_3_35_1","unstructured":"WIdO\u2013Wissenschaftliches Institut der AOK. Anatomisch-therapeutischchemische Klassifikation mit Tagesdosen: amtliche Fassung des ATC-Index mit DDD-Angaben f\u00fcr Deutschland im Jahre 2022; 2022 [cited 2023 Jan 31]. Available from: https:\/\/www.wido.de\/publikationen-produkte\/arzneimittel-klassifikation\/"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31280-1"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-1201"},{"key":"e_1_3_3_38_1","unstructured":"Bundesministerium f\u00fcr Gesundheit. Mitglieder und Versicherte der Gesetzlichen Krankenversicherung (GKV); 2019 [cited 2023 Jan 31]. Available from: https:\/\/www.bundesgesundheitsministerium.de\/themen\/krankenversicherung\/zahlen-und-fakten-zur-krankenversicherung\/mitglieder-und-versicherte.html"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047806"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265741"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4245"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14508"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1329009"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17735756"},{"key":"e_1_3_3_45_1","unstructured":"European Medicines Agency. Enbrel (Etanercept); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enbrel"},{"key":"e_1_3_3_46_1","unstructured":"European Medicines Agency. Cimzia (Certolizumab pegol); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cimzia-0"},{"key":"e_1_3_3_47_1","unstructured":"European Medicines Agency. Humira (adalimumab); 2022 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira#:\u223c:text=Humira%20received%20a%20marketing%20authorisation EU%20on%208%20September%202003"},{"key":"e_1_3_3_48_1","unstructured":"European Medicines Agency. Remicade (Infliximab); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remicade"},{"key":"e_1_3_3_49_1","unstructured":"Novartis. Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis; 2015 [cited 2023 Dec 6]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-two-landmark-european-approvals-cosentyx-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis#:\u223c:text=Basel%2C%20November%2023%2C%202015%20%2D and%20psoriatic%20arthritis%20(PsA)"},{"key":"e_1_3_3_50_1","unstructured":"Johnson & Johnson. STELARA\u00ae receives european commission approval for treatment of active psoriatic arthritis; 2013 [cited 2023 Dec 6]. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/stelara-receives-european-commission-approval-for-treatment-of-active-psoriatic-arthritis#:\u223c:text=Beerse%2C%20Belgium%2C%20September%2023%2C the%20response%20to%20previous%20non%2D"},{"key":"e_1_3_3_51_1","unstructured":"PharmaTimes. Lilly\u2019s Taltz wins EU approval for psoriatic arthritis; 2018 [cited 2023 Dec 6]. Available from: https:\/\/www.pharmatimes.com\/news\/lillys_taltz_wins_eu_approval_for_psoriatic_arthritis_1218507"},{"key":"e_1_3_3_52_1","unstructured":"European Medicines Agency. Cosentyx (Secukinumab); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cosentyx"},{"key":"e_1_3_3_53_1","unstructured":"European Medicines Agency. Stelara (Ustekinumab); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara"},{"key":"e_1_3_3_54_1","unstructured":"European Medicines Agency. Taltz (Ixekizumab); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taltz"},{"key":"e_1_3_3_55_1","unstructured":"European Medicines Agency. Kyntheum (Brodalumab); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kyntheum#ema-inpage-item-authorisation-details"},{"key":"e_1_3_3_56_1","unstructured":"European Medicines Agency. Skyrizi (Risankizumab); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi"},{"key":"e_1_3_3_57_1","unstructured":"European Medicines Agency. Tremfya (Guselkumab); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tremfya#ema-inpage-item-authorisation-details"},{"key":"e_1_3_3_58_1","unstructured":"European Medicines Agency. Ilumetri (Tildrakizumab); 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri#ema-inpage-item-authorisation-details"},{"key":"e_1_3_3_59_1","unstructured":"AbbVie. AbbVie expands immunology portfolio in the European Union with the European Commission approval of SKYRIZI\u00ae (risankizumab) for the treatment of adults with active psoriatic arthritis; 2021 [cited 2023 Dec 6]. Available from: https:\/\/news.abbvie.com\/2021-11-17-AbbVie-Expands-Immunology-Portfolio-in-the-European-Union-with-the-European-Commission-Approval-of-SKYRIZI-R-risankizumab-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis"},{"key":"e_1_3_3_60_1","unstructured":"Janssen. European Commission approves Janssen\u2019s TREMFYA\u00ae (guselkumab) a first-in-class treatment for active psoriatic arthritis (PsA); 2020 [cited 2023 Dec 6]. Available from: https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/f2e60a79-e1ac-4544-8456-5f54cbd55331"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880201"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18409"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18047"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00658-x"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16431"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0256-7"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2214046"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.02.003"},{"key":"e_1_3_3_71_1","unstructured":"Gemeinsamer Bundesausschuss. Medicinal Products Directive\/Appendix IX and X: fixed amount grouping and comparator update\u2014TNF-alpha inhibitors group 1 in stage 2; 2021 [cited 2023 Nov 17]. Available from: https:\/\/www.g-ba.de\/beschluesse\/4550\/"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18798"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00598-4"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23455"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15628"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2452054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:48:01Z","timestamp":1766400481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2452054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2452054"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2452054","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}